180 Life Sciences Corp. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation

Reuters

Jul 01, 2025

<a href="https://laohu8.com/S/ATNF">180 Life Sciences Corp</a>. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation

180 Life Sciences Corp. has announced significant enhancements to its intellectual property portfolio with the allowance of protection for two critical therapeutic areas. The Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering a method for treating localized fibrotic disorders, such as Dupuytren's Disease and Frozen Shoulder, using an IL-33 antagonist. Additionally, the United States Patent and Trademark Office has granted a patent for methods and agents aimed at preventing or reducing post-operative cognitive decline. These developments are expected to strengthen the company's proprietary platform and enhance shareholder value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 180 Life Sciences Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1044620) on July 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2548005206"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548005206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548005206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-01 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548005206","market":"nz","top_or_hot":-1,"title":"180 Life Sciences Corp. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATNF\">180 Life Sciences Corp</a>. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        180 Life Sciences Corp. has announced significant enhancements to its intellectual property portfolio with the allowance of protection for two critical therapeutic areas. The Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering a method for treating localized fibrotic disorders, such as Dupuytren's Disease and Frozen Shoulder, using an IL-33 antagonist. Additionally, the United States Patent and Trademark Office has granted a patent for methods and agents aimed at preventing or reducing post-operative cognitive decline. These developments are expected to strengthen the company's proprietary platform and enhance shareholder value.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 180 Life Sciences Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1044620) on July 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>180 Life Sciences Corp. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n180 Life Sciences Corp. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-01 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATNF\">180 Life Sciences Corp</a>. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        180 Life Sciences Corp. has announced significant enhancements to its intellectual property portfolio with the allowance of protection for two critical therapeutic areas. The Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering a method for treating localized fibrotic disorders, such as Dupuytren's Disease and Frozen Shoulder, using an IL-33 antagonist. Additionally, the United States Patent and Trademark Office has granted a patent for methods and agents aimed at preventing or reducing post-operative cognitive decline. These developments are expected to strengthen the company's proprietary platform and enhance shareholder value.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 180 Life Sciences Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1044620) on July 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL9Hwsdj:1","article_id":"2548005206","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548005206","pubTimestamp":1751370150,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"180 Life Sciences Corp. has announced significant enhancements to its intellectual property portfolio with the allowance of protection for two critical therapeutic areas. The Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering a method for treating localized fibrotic disorders, such as Dupuytren's Disease and Frozen Shoulder, using an IL-33 antagonist. Additionally, the United States Patent and Trademark Office has granted a patent for methods and agents aimed at preventing or reducing post-operative cognitive decline. These developments are expected to strengthen the company's proprietary platform and enhance shareholder value.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 180 Life","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"180 Life Sciences Corp.通过针对纤维化疾病和神经炎症的新专利授权加强知识产权组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATNF":0.9},"content_text":"180 Life Sciences Corp. Strengthens IP Portfolio with New Patent Allowances for Fibrotic Disorders and Neuroinflammation\n    \n\n        180 Life Sciences Corp. has announced significant enhancements to its intellectual property portfolio with the allowance of protection for two critical therapeutic areas. The Canadian Intellectual Property Office has issued a Notice of Allowance for a patent application covering a method for treating localized fibrotic disorders, such as Dupuytren's Disease and Frozen Shoulder, using an IL-33 antagonist. Additionally, the United States Patent and Trademark Office has granted a patent for methods and agents aimed at preventing or reducing post-operative cognitive decline. These developments are expected to strengthen the company's proprietary platform and enhance shareholder value.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 180 Life Sciences Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1044620) on July 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}